Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
出版年份 2015 全文链接
标题
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
作者
关键词
Ovarian Carcinoma, Trabectedin, Checkpoint Inhibitor, Tumor Protection, Peritoneal Lavage Fluid
出版物
Journal of Translational Medicine
Volume 13, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-07-28
DOI
10.1186/s12967-015-0613-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells
- (2015) Hyangsoon Noh et al. Cell Communication and Signaling
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- (2015) Daniel Sanghoon Shin et al. CURRENT OPINION IN IMMUNOLOGY
- Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
- (2015) Christina Wefers et al. GYNECOLOGIC ONCOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint modulation: Rational design of combination strategies
- (2015) Dmitriy Zamarin et al. PHARMACOLOGY & THERAPEUTICS
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
- (2014) Zhiqiang Guo et al. PLoS One
- Checkpoint inhibitors in immunotherapy of ovarian cancer
- (2014) Dong-hui Wang et al. TUMOR BIOLOGY
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
- (2013) Giovanni Germano et al. CANCER CELL
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
- (2013) Zhiqiang Guo et al. Journal of Translational Medicine
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
- (2013) Huafeng Wei et al. PLoS One
- CD4 CTL: Living up to the challenge
- (2013) Hilde Cheroutre et al. SEMINARS IN IMMUNOLOGY
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
- (2012) Renee Vermeij et al. CURRENT PHARMACEUTICAL DESIGN
- Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
- (2012) Bradley J. Monk et al. EUROPEAN JOURNAL OF CANCER
- Silencing of the TGF-β1 Gene Increases the Immunogenicity of Cells From Human Ovarian Carcinoma
- (2012) Huafeng Wei et al. JOURNAL OF IMMUNOTHERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Immunotherapy in ovarian cancer
- (2012) Gina M. Mantia-Smaldone et al. Human Vaccines & Immunotherapeutics
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy for Ovarian Cancer: What's Next?
- (2010) Lana E. Kandalaft et al. JOURNAL OF CLINICAL ONCOLOGY
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More